Cancer Causes Control
Cancer Causes & Control 
0957-5243
1573-7225
Kluwer Academic Publishers
Dordrecht


2039842
17636402
9032
10.1007/s10552-007-9032-6
Original Paper


APC
KRAS
 genes

Weijenberg
Matty P.

mp.weijenberg@epid.unimaas.nl

1

Lüchtenborg
Margreet

2

de Goeij
Anton F. P. M.

3

Brink
Mirian

4

van Muijen
Goos N. P.

5

de Bruïne
Adriaan P.

3

Goldbohm
R. Alexandra

6

van den Brandt
Piet A.

1

1
Department of Epidemiology, Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands 
2
Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI USA 
3
Research Institute Growth and Development (GROW), Department of Pathology, Maastricht University, Maastricht, The Netherlands 
4
Comprehensive Cancer Center, IKMN, Utrecht, The Netherlands 
5
Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 
6
TNO Nutrition and Food Research, Zeist, The Netherlands 

18
7
2007

10
2007

18
8
865
879
7
6
2006

20
6
2007


© Springer Science + Business Media B.V. 2007

Objective
APC
KRAS
 (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) oncogene.

Methods
n
 = 120,852), adjusted incidence rate ratios (RR) and 95% confidence intervals (CI) were computed, based on 401 colon and 130 rectal cancer patients.

Results
KRAS
APC
p
APC
.

Conclusion
KRAS
APC
 gene and MLH1 expression, suggesting a unique etiology of tumors with specific genetic aberrations.


Keywords
Dietary Fats
Colorectal Neoplasms
Epidemiology
Molecular

issue-copyright-statement
© Springer Science + Business Media B.V. 2007




Introduction
1
2
3
4
5
]. This approach may improve our ability to observe associations between dietary factors and cancer that may otherwise remain undetected.
6
8
9
10
11
APC
TP53
KRAS
12
13
14
APC
8
15
KRAS
15
TP53
15
].
16
vice versa
17
18
19
20
21
KRAS
22
].
APC
KRAS
 gene mutations.

Materials and methods
Study population
23
24
]. The NCR and PALGA together provide a near 100% coverage of the 204 municipalities included in the NLCS.
24
1
Fig. 1
a
b
c
d
e
f
g
h
Patients with rectal tumors were not included in the analysis according to MLH1 expression




The first 2.3 years of follow up were excluded because of possible preclinical disease affecting exposure status and because of incomplete nationwide coverage of PALGA alone (i.e., not in combination with the NCR) in some of the municipalities included in the NLCS. Within this period, 83 subcohort members deceased or were diagnosed with cancer other than non-melanoma skin cancer, leaving 3,263 subcohort members for analysis. From 1989 to 1994, 929 incident cases with histologically confirmed colorectal cancer were identified within the entire cohort, of whom 819 could also be linked to a PALGA report of the lesion. The PALGA reports were used to identify and locate tumor tissues from eligible colorectal cancer patients in 54 pathology laboratories throughout the Netherlands. Cancers were classified according to site as follows, colon: cecum through sigmoid colon (ICD-O codes 153:0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7), proximal colon (ICD-O codes 153.0, 153.1, 153.4, 153.5, 153.6), distal colon (ICD-O codes 153.2, 153,3, `53.7), rectosigmoid (ICD-O code 154.0), and rectum (ICD-O code 154.1).

Tissue samples
APC
KRAS
 genes.
Since the rectosigmoid can be considered as a clinically applied term rather than an anatomically defined transitional zone between the colon and rectum, the 85 patients with a rectosigmoid tumor were excluded from data analysis. Moreover, the group of patients with a rectosigmoid tumor was too small for adequate stratified analysis.

MLH1 expression analysis
2
2
. Slides were submitted to microwave antigen retrieval in 1mM EDTA buffer (pH 8.0) and incubated with 10% normal horse serum for 10 min at room temperature. Then, sections were incubated overnight at 4°C with mouse monoclonal antibodies against MLH1 protein (clone G168–15, PharMingen, San Diego, CA) at a 1:100 dilution. Antibody binding was detected by incubating the sections at room temperature with the peroxidase-labeled DAKO Envision System (DAKO, Carpinteris, CA) and using DAB as a chromogen. Sections were counterstained with haematoxylin.
1
).

APC
 mutation analysis
APC
25
APC
APC
25
26
APC 
25
25
APC
25
].
APC
APC
1
).

KRAS
 mutation analysis
KRAS
27
KRAS
27
1
).

Exposure assessment
28
29
29
]. For energy intake the correlation coefficient was 0.74. On average, the questionnaire covered 91% of the energy intake assessed by the record intake. Questionnaire data were key-entered twice and processed for all incident cases in the cohort and for all subcohort members in a manner blinded with respect to case/subcohort status.
29
APC
KRAS
1
).
30
31
2
), non-occupational physical activity (<30 min/day, 30–60 min/day, 60–90 min/day, >90 min/day), family history of colorectal cancer (yes/no) and smoking status (never/ex/current) were regarded as potential confounders.

Statistical analysis
APC
KRAS
1
).
APC
APC
+
APC
− 
APC
APC
APC
KRAS
KRAS
22
KRAS
.
APC
KRAS
KRAS
KRAS
 gene leading to an altered amino acid.
2
APC
APC
U
APC
2
–test.
Incidence rate ratios (RR) and corresponding 95% confidence intervals (CI) for colon and rectal cancer patients were estimated according to quartiles of intake of fat variables, and one standard deviation increment of intake, using Cox proportional hazards regression models. In addition, associations were estimated for specific molecular endpoints of the tumors.
32
33
34
]. Tests for dose response trends over the different quartiles and categories of fat intake were estimated by fitting the ordinal exposure variables as continuous variables and evaluated using the Wald test.
p
 < 0.05) contribute to the multivariate model for colon and/or rectal cancer (age at baseline, sex, body mass index, family history of colorectal cancer, and smoking status) or to influence the RR by more than ten percent, as well as energy intake.


Results
1
APC
1
APC
25
Table 1
Baseline dietary intake and other characteristics of the subcohort and colon and rectum cancer patients from The Netherlands cohort study


Subcohort
n 
= 428)
p
b

n
 = 401)
p
b

n
 = 130)
p
b


a

a

APC 
c

APC 
c

APC 
c

APC  
c



N

2,948
374
54

274
127

73
57


    Sex (%men)
48
56
41
0.04

52
56
0.49

64
67
0.79


    Age (years)
61.3 ± 4.2
63.0 ± 4.0
62.8 ± 4.5
0.91

63.1 ± 4.0
62.7 ± 4.0
0.34

62.2 ± 4.4
62.6 ± 3.5
0.63


d


    Total fat
83.8 ± 15.8
85.1 ± 14.7
84.1 ± 17.5
0.57

85.2 ± 15.0
84.8 ± 14.9
0.80

85.1 ± 14.2
86.7 ± 14.8
0.52


    Saturated fat
33.2 ± 7.5
33.5 ± 6.6
33.3 ± 7.6
0.64

33.3 ± 6.7
33.5 ± 7.0
0.92

33.0 ± 5.8
35.5 ± 7.7
0.05


e

31.4 ± 7.0
31.9 ± 6.5
31.1 ± 7.5
0.45

31.8 ± 6.6
31.9 ± 6.6
0.98

31.8 ± 6.1
32.8 ± 6.2
0.37


f

17.3 ± 7.5
17.9 ± 7.5
17.4 ± 6.8
0.85

18.2 ± 7.3
17.8 ± 7.6
0.44

18.6 ± 8.7
16.5 ± 6.9
0.27


    Linoleic acid
16.0 ± 7.5
16.7 ± 7.5
16.6 ± 7.0
0.76

17.0 ± 7.4
16.6 ± 7.7
0.36

17.5 ± 8.8
15.2 ± 7.2
0.15


    Linolenic acid
1.3 ± 0.6
1.2 ± 0.5
1.3 ± 0.6
0.98

1.2 ± 0.5
1.3 ± 0.5
0.57

1.3 ± 0.6
1.3 ± 0.6
0.79


Other dietary factors

    Fibre (g/day)
27.0 ± 8.2
24.5 ± 8.1
25.2 ± 7.1
0.13

26.7 ± 7.9
27.9 ± 8.1
0.20

28.1 ± 7.0
28.2 ± 9.0
0.78


g

10.1 ± 14.1
11.0 ± 14.8
10.7 ± 17.0
0.49

11.0 ± 14.9
11.3 ± 16.5
0.89

12.2 ± 14.9
14.5 ± 18.1
0.53


    Fruit (g/day)
177.0 ± 118.0
178.8 ± 122.1
160.5 ± 137.7
0.07

169.7 ± 121.9
187.5 ± 132.2
0.11

197.4 ± 155.1
205.0 ± 118.3
0.21


    Vegetables (g/day)
193.8 ± 82.2
191.3 ± 82.3
185.4 ± 73.8
0.80

187.9 ± 80.7
192.7 ± 85.2
0.71

186.3 ± 68.5
169.0 ± 122.2
0.69


    Energy (kj/day)
8,028 ± 2,164
8,080 ± 2,059
7,505 ± 1,718
0.07

7,845 ± 1,899
8,335 ± 2,306
0.09

8,433 ± 1,924
8,449 ± 1,616
0.92


Other characteristics

h
2
)
25.1 ± 3.1
25.6 ± 3.2
25.6 ± 3.5
0.57

25.5 ± 3.28
25.8 ± 3.1
0.30

25.3 ± 3.1
25.1 ± 2.8
0.92


i
 (% yes)
6
13
9
0.49

11
11
0.98

10
11
0.86


Smoker (%)

    Never
37
37
33

36
38

26
33


    Ex-smoker
35
45
37

46
43

47
39


    Current smoker
28
18
30
0.12

18
19
0.88

27
28
0.59


g


    <30 min/day
21
21
22

19
26

17
26


    30-60 min/day
32
33
22

33
28

28
32


    60-90 min/day
21
21
19

22
18

24
18


    >90 min/day
27
25
37
0.20

26
27
0.31

32
25
0.43




a
MLH1
 expression, these are not shown separately in this table
b
p
MLH1
APC

c
APC 
APC
APC
 gene leading to a stop codon
d
Adjusted for energy intake
e
Monounsaturated fat
f
Polyunsaturated fat
g
For alcohol intake and physical activity the mean levels in the subcohort are based on 2,862 and 2,915 subjects respectively. Four and six colon cancer cases had missing values for alcohol intake and physical activity respectively. Two and one rectal cancer case had missing values for alcohol intake and physical activity respectively
h
BMI: body mass index
i
CRC: colorectal cancer



1
APC
APC
APC
p 
= 0.05).
2
APC
APC
APC
2
p 
APC
p
2
APC
Table 2
MLH1
APC
 mutation leading to a stop codon, according to the intake of fat variables (The Netherlands Cohort Study)

Dietary fat intake
Median intake (g/day)
b

Colon cancer

Overall
No MLH1 expression
APC
a

APC 
a


Men
Women
Number of patients
c

c

Number of patients
c

c

Number of patients
c

c

Number of patients
c

c



Total fat

    Q1
78.0
63.0
3,549
110
1.00
(reference)

11
1.00
(reference)

61
1.00
(reference)

40
1.00
(reference)


    Q2
90.2
71.4
3,556
125
1.09
(0.82–1.44)
17
1.47
(0.69–3.14)
87
1.34
(0.94–1.90)
32
0.80
(0.49–1.28)

    Q3
98.5
77.6
3,579
89
0.75
(0.55–1.01)
11
0.94
(0.40–2.17)
55
0.82
(0.56–1.21)
24
0.57
(0.33–0.96)

    Q4
108.8
85.3
3,588
110
0.96
(0.72–1.28)
15
1.30
(0.59–2.86)
71
1.11
(0.77–1.59)
31
0.74
(0.46–1.20)

    p
d





0.29



0.82



0.71



0.13



e





1.00
(0.88–1.13)

1.21
(0.82–1.77)

1.04
(0.89–1.22)

0.93
(0.76–1.14)

Saturated fat

    Q1
28.9
23.9
3,567
99
1.00
(reference)

9
1.00
(reference)

59
1.00
(reference)

33
1.00
(reference)


    Q2
33.7
27.8
3,550
120
1.20
(0.89–1.61)
14
1.48
(0.63–3.49)
84
1.38
(0.97–1.97)
30
0.94
(0.55–1.61)

    Q3
38.3
30.9
3,583
115
1.11
(0.82–1.49)
19
1.93
(0.86–4.32)
73
1.15
(0.79–1.66)
33
1.01
(0.60–1.68)

    Q4
45.8
36.6
3,571
100
0.94
(0.69–1.27)
12
1.25
(0.52–3.00)
58
0.90
(0.62–1.32)
31
0.89
(0.53–1.48)

    p
d





0.54



0.48



0.35



0.72



e





0.97
(0.87–1.08)

1.12
(0.82–1.51)

0.95
(0.83–1.09)

0.95
(0.79–1.14)

f


    Q1
28.2
22.4
3,546
98
1.00
(reference)

11
1.00
(reference)

56
1.00
(reference)

31
1.00
(reference)


    Q2
33.2
26.0
3,546
122
1.20
(0.89–1.61)
14
1.15
(0.52–2.53)
79
1.33
(0.92–1.91)
36
1.18
(0.72–1.95)

    Q3
36.9
28.9
3,580
113
1.12
(0.83–1.52)
14
1.15
(0.52–2.54)
76
1.30
(0.89–1.89)
31
1.03
(0.60–1.77)

    Q4
42.5
33.1
3,600
101
0.99
(0.73–1.34)
15
1.25
(0.58–2.71)
63
1.08
(0.74–1.57)
29
0.90
(0.54–1.52)

    p
d





0.79



0.59



0.80



0.57



e





0.99
(0.88–1.12)

1.04
(0.73–1.46)

1.01
(0.87–1.17)

0.98
(0.81–1.18)

g


    Q1
11.6
8.8
3,507
91
1.00
(reference)

8
1.00
(reference)

49
1.00
(reference)

32
1.00
(reference)


    Q2
16.0
12.4
3,562
118
1.37
(1.02–1.86)
16
2.03
(0.86–4.81)
73
1.55
(1.06–2.28)
33
1.13
(0.68–1.89)

    Q3
20.9
16.2
3,618
113
1.24
(0.91–1.68)
16
2.00
(0.84–4.76)
78
1.57
(1.07–2.31)
30
0.96
(0.57–1.62)

    Q4
29.3
22.5
3,580
112
1.21
(0.89–1.63)
14
1.75
(0.72–4.24)
74
1.47
(1.01–2.16)
32
0.98
(0.59–1.63)

    p
d





0.38



0.26



0.06



0.79



e





1.03
(0.94–1.14)

1.07
(0.82–1.38)

1.09
(0.97–1.23)

1.00
(0.84–1.19)

Linoleic acid

    Q1
10.0
7.5
3,509
86
1.00
(reference)

8
1.00
(reference)

49
1.00
(reference)

26
1.00
(reference)


    Q2
14.8
11.2
3,586
122
1.49
(1.10–2.02)
13
1.66
(0.69–3.98)
71
1.50
(1.02–2.21)
40
1.65
(0.99–2.76)

    Q3
19.5
14.9
3,599
112
1.32
(0.97–1.79)
17
2.14
(0.91–5.00)
82
1.68
(1.15–2.45)
25
1.00
(0.57–1.76)

    Q4
28.0
21.2
3,574
114
1.30
(0.96–1.77)
16
2.02
(0.86–4.76)
72
1.44
(0.99–2.11)
36
1.35
(0.80–2.28)

    p
d





0.20



0.08



0.05



0.65



e





1.06
(0.96–1.17)

1.15
(0.90–1.48)

1.12
(0.99–1.26)

1.02
(0.86–1.21)

Linolenic acid

    Q1
0.8
0.6
3,518
107
1.00
(reference)

11
1.00
(reference)

68
1.00
(reference)

31
1.00
(reference)


    Q2
1.2
0.9
3,574
104
0.95
(0.70–1.30)
17
1.32
(0.60–2.89)
72
0.99
(0.68–1.43)
24
0.84
(0.47–1.49)

    Q3
1.5
1.2
3,571
117
1.10
(0.82–1.48)
11
0.91
(0.40–2.10)
62
0.89
(0.62–1.29)
43
1.48
(0.91–2.40)

    Q4
2.0
1.6
3,604
106
1.01
(0.76–1.36)
15
1.32
(0.61–2.84)
72
1.08
(0.76–1.53)
29
0.97
(0.57–1.65)

    p
d





0.68



0.73



0.82



0.52



e





0.98
(0.89–1.09)

1.07
(0.79–1.44)

0.97
(0.85–1.10)

1.01
(0.86–1.19)



a
APC 
APC
APC
 gene leading to a stop codon
b
Person years at risk are estimated from the subcohort
c
Incidence rate ratios (RR) and 95% confidence intervals (95% CI) are adjusted for age, sex, body mass index, smoking, energy intake and family history of colorectal cancer
d
p
-value for trend over the quartiles of intake of fat variables
e
1
); i.e., 15.8 g/day for total fat, 7.5 g/day for saturated fat, 7.0 g/day for monounsaturated fat, 7.5 g/day for polyunsaturated fat, 7.5 g/day for linoleic acid and 0.6 g/day for linolenic acid
f
Monounsaturated fat
g
Polyunsaturated fat



3
APC
APC
p
3
APC
Table 3
APC
 mutation leading to a stop codon, according to the intake of fat variables. (The Netherlands Cohort Study)

Dietary fat intake
Median intake (g/day)
b

Rectal cancer

Overall
APC
a

APC 
a


Men
Women
Number of patients
c

c

Number of patients
c

c

Number of patients
c

c



Total fat

    Q1
78.0
63.0
3,549
43
1.00
(reference)

24
1.00
(reference)

15
1.00
(reference)


    Q2
90.2
71.4
3,556
39
0.89
(0.56–1.39)
17
0.70
(0.37–1.34)
12
0.79
(0.36–1.70)

    Q3
98.5
77.6
3,579
33
0.74
(0.46–1.19)
16
0.65
(0.33–1.26)
14
0.91
(0.43–1.90)

    Q4
108.8
85.3
3,588
38
0.87
(0.55–1.36)
15
0.60
(0.31–1.16)
16
1.06
(0.51–2.19)

    p
d





0.42



0.13



0.80



e





0.91
(0.76–1.09)

0.84
(0.65–1.08)

0.94
(0.69–1.28)

Saturated fat

    Q1
28.9
23.9
3,567
43
1.00
(reference)

23
1.00
(reference)

14
1.00
(reference)


    Q2
33.7
27.8
3,550
34
0.80
(0.49–1.29)
18
0.81
(0.42–1.56)
12
0.87
(0.39–1.91)

    Q3
38.3
30.9
3,583
44
1.02
(0.66–1.59)
21
0.92
(0.49–1.73)
12
0.86
(0.40–1.88)

    Q4
45.8
36.6
3,571
33
0.74
(0.46–1.18)
11
0.46
(0.22–0.97)
19
1.30
(0.65–2.63)

    p
d





0.38



0.07



0.47



e





0.95
(0.81–1.12)

0.81
(0.65–1.02)

1.16
(0.89–1.50)

f


    Q1
28.2
22.4
3,546
44
1.00
(reference)

23
1.00
(reference)

15
1.00
(reference)


    Q2
33.2
26.0
3,546
31
0.70
(0.44–1.13)
18
0.79
(0.41–1.49)
9
0.62
(0.27–1.43)

    Q3
36.9
28.9
3,580
40
0.91
(0.58–1.44)
15
0.67
(0.34–1.33)
20
1.36
(0.67–2.78)

    Q4
42.5
33.1
3,600
39
0.88
(0.56–1.37)
17
0.72
(0.38–1.36)
13
0.88
(0.40–1.90)

    p
d





0.82



0.28



0.76



e





0.94
(0.78–1.12)

0.85
(0.67–1.08)

1.00
(0.76–1.33)

g


    Q1
11.6
8.8
3,507
45
1.00
(reference)

17
1.00
(reference)

21
1.00
(reference)


    Q2
16.0
12.4
3,562
32
0.74
(0.46–1.18)
19
1.17
(0.60–2.28)
10
0.49
(0.23–1.07)

    Q3
20.9
16.2
3,618
39
0.86
(0.55–1.34)
16
0.94
(0.47–1.88)
16
0.76
(0.39–1.48)

    Q4
29.3
22.5
3,580
38
0.82
(0.53–1.29)
21
1.20
(0.63–2.29)
10
0.47
(0.22–1.00)

    p
d





0.53



0.73



0.11



e





0.98
(0.83–1.16)

1.06
(0.84–1.34)

0.78
(0.60–1.03)

Linoleic acid

    Q1
10.0
7.5
3,509
39
1.00
(reference)

18
1.00
(reference)

18
1.00
(reference)


    Q2
14.8
11.2
3,586
39
1.03
(0.65–1.64)
17
0.98
(0.50–1.92)
14
0.80
(0.40–1.63)

    Q3
19.5
14.9
3,599
35
0.90
(0.56–1.44)
16
0.90
(0.45–1.79)
15
0.84
(0.42–1.68)

    Q4
28.0
21.2
3,574
41
1.03
(0.65–1.62)
22
1.19
(0.63–2.24)
10
0.54
(0.25–1.18)

    p
d





0.95



0.65



0.15



e





0.99
(0.84–1.17)

1.09
(0.86–1.38)

0.79
(0.60–1.04)

Linolenic acid

    Q1
0.8
0.6
3,518
42
1.00
(reference)

18
1.00
(reference)

18
1.00
(reference)


    Q2
1.2
0.9
3,574
38
0.92
(0.57–1.48)
20
1.16
(0.58–2.31)
10
0.55
(0.25–1.24)

    Q3
1.5
1.2
3,571
36
0.87
(0.55–1.38)
15
0.87
(0.43–1.75)
13
0.72
(0.35–1.48)

    Q4
2.0
1.6
3604
38
0.92
(0.58–1.44)
20
1.13
(0.60–2.14)
16
0.90
(0.45–1.80)

    p
d





0.68



0.93



0.91



e





0.95
(0.81–1.12)

0.98
(0.77–1.24)

1.03
(0.81–1.31)



a
APC 
APC
APC
 gene leading to a stop codon
b
Person years at risk are estimated from the subcohort
c
Incidence rate ratios (RR) and 95% confidence intervals (95% CI) are adjusted for age, sex, body mass index, smoking, energy intake and family history of colorectal cancer
d
p
-value for trend over the quartiles of intake of fat variables
e
1
); i.e., 15.8 g/day for total fat, 7.5 g/day for saturated fat, 7.0 g/day for monounsaturated fat, 7.5 g/day for polyunsaturated fat, 7.5 g/day for linoleic acid and 0.6 g/day for linolenic acid
f
Monounsaturated fat
g
Polyunsaturated fat



APC
KRAS
22
KRAS
p
APC
p
APC
4
KRAS
4
p
p
Table 4
APC
KRAS
 gene mutation, according to the intake of polyunsaturated fat and linoleic acid intake (The Netherlands Cohort Study)

Dietary fat intake
e

Colon cancer

a

b

APC
c

KRAS
d




Number of patients
f

f

Number of patients
f

f

Number of patients
f

f

Number of patients
f

f



g


Q1
3,507
39
1.00
(reference)

6
1.00
(reference)

18
1.00
(reference)

4
1.00
(reference)


Q2
3,562
44
1.15
(0.73–1.81)
14
2.48
(0.94–6.54)
21
1.31
(0.68–2.53)
14
3.76
(1.21–11.69)

Q3
3,618
45
1.10
(0.70–1.73)
11
1.89
(0.69–5.16)
15
0.86
(0.43–1.74)
19
5.00
(1.67–14.99)

Q4
3,580
35
0.86
(0.54–1.38)
10
1.72
(0.61–4.81)
13
0.70
(0.34–1.45)
28
6.74
(2.36–19.51)

p
h



0.51



0.48



0.19



≤0.001



i



0.96
(0.82–1.13)

1.01
(0.72–1.40)

0.90
(0.71–1.14)

1.40
(1.17–1.68)

Linoleic acid

Q1
3,509
38
1.00
(reference)

7
1.00
(reference)

14
1.00
(reference)

4
1.00
(reference)


Q2
3,586
45
1.20
(0.77–1.90)
10
1.51
(0.58–0.93)
26
2.03
(1.03–3.99)
15
4.06
(1.32–12.46)

Q3
3,599
45
1.15
(0.73–1.81)
14
2.08
(0.84–5.19)
13
0.99
(0.46–2.13)
21
5.61
(1.88–16.68)

Q4
3,574
35
0.90
(0.56–1.44)
10
1.49
(0.56–3.97)
14
0.97
(0.46–2.06)
25
6.02
(2.09–17.41)

p
h



0.62



0.30



0.38



≤0.001



i



0.98
(0.84–1.15)

1.08
(0.79–1.49)

0.91
(0.73–1.14)

1.41
(1.18–1.69)



a
APC
KRAS
 gene mutations
b
APC
KRAS
 gene mutations
c
APC
KRAS
 gene mutations
d
KRAS
APC
 gene mutations
e
Person years at risk are estimated from the subcohort.
f
Incidence rate ratios (RR) and 95% confidence intervals (95% CI) are adjusted for age, sex, body mass index, smoking, energy intake and family history of colorectal cancer.
g
Polyunsaturated fat
h
p
-value for trend over the quartiles of intake of fat variables
i
1
); i.e., 7.5 g/day for polyunsaturated fat and 7.5 g/day for linoleic acid



APC
KRAS
p
-trend = 0.09).

Discussion
APC
KRAS
APC
 mutation or lack of MLH1 expression.
35
43
35
38
41
42
] including the current study.
APC
38
APC
KRAS
APC
 mutation. However, the association was weak, did not increase gradually according to the quartiles of intake and was only a result of the reduced risk in the highest category of intake. Furthermore, in absence of a biological explanation for this finding and considering the large number of associations investigated, the observation may best be attributed to chance.
KRAS
41
KRAS
22
].
KRAS
35
42
].
40
35
39
41
43
37
40
42
35
37
42
].
KRAS
22
KRAS
APC
KRAS
27
18
19
21
]. Therefore, even though chance cannot be ruled out and verification by others is warranted, the association seems quite plausible.
KRAS
7
8
15
33
].
KRAS
APC
KRAS
APC
25
APC
 did not show any associations with the intake of fat or different types of fat.
KRAS
APC
KRAS
KRAS
APC
KRAS
APC
KRAS
TP53
44
TP53
4
16
KRAS
 mutated pathway.
KRAS
APC
 gene and MLH1 expression. Verification in other studies is warranted. Possibly, tumors revealing the involvement of distinct genetic pathways on the basis of specific genetic aberrations, may have a unique etiology.


We thank Dr. P. Wark and G. van Wijhe for assessing MLH1 expression. We are grateful to Prof. J.W. Arends and Dr. M. van Engeland for their participation in the initiation of the study. In addition, we thank Drs. A. Volovics and A. Kester for statistical advice; Dr. L. Schouten, S. van de Crommert, H. Brants, J. Nelissen, C. de Zwart, M. Moll, W. van Dijk, M. Jansen, and A. Pisters for assistance; and H. van Montfort, T. van Moergastel, L. van den Bosch, and R. Schmeitz for programming assistance. We also thank the participants of this study and wish to thank the regional cancer registries (IKA, IKL, IKMN, IKN, IKO, IKR, IKST, IKW, IKZ), and the Dutch nationwide network and registry of histo- and cytopathology (PALGA). Finally, we are grateful to the departments of Pathology of the following hospitals for providing the tissue blocks: Academisch Ziekenhuis Nijmegen Sint Radboud, Academisch Ziekenhuis Groningen, Rijnland Ziekenhuis, Antoni van Leeuwenhoek Ziekenhuis, Academisch Ziekenhuis Rotterdam, Stichting Laboratorium Pathologie Oost Nederland, Pathologisch Instituut Utrecht, Ziekenhuis Rijnstate Arnhem, Laboratorium Volksgezondheid Leeuwarden, Ziekenhuis Bethesda, Stichting Samenwerkend Ziekenhuizen Oost Groningen, Martini Ziekenhuis Groningen, Samenwerkend Stichting Delftse Ziekenhuizen, Leyenburg Ziekenhuis, Academisch Ziekenhuis Vrije Universiteit, Academisch Medisch Centrum, Sint Franciscus Ziekenhuis, Dr. Daniel den Hoed Kliniek, Academisch Ziekenhuis Maastricht, Goudse Ziekenhuizen Stichting Laboratorium, Canisius Wilhelmina Ziekenhuis, Slootervaart Ziekenhuis, Maaslandziekenhuis, Atrium Heerlen, Atrium Kerkrade and Brunssum, Microbiologie St. Medische Stedendriehoek, IJsselmeer Ziekenhuizen, Ziekenhuis Centrum Apeldoorn, Isala Klinieken, Elkeriekziekenhuis, Groot Ziekengasthuis, Ziekenhuis Gooi Noord, Medisch Centrum Alkmaar, Regionaal Pathologisch en Cytologisch Laboratorium voor Eemland en Noord-West Veluwe, Diakonesse Ziekenhuis, Sint Antonius Ziekenhuis, Onze Lieve Vrouwe Gasthuis, St. Lucas Andreas Ziekenhuis, Pathologisch Anatomisch Laboratorium SPALK, Ziekenhuis de Heel, Diakonessenhuis, Rode Kruis Ziekenhuis, Ziekenhuis Bronovo, Laurentius Ziekenhuis Roermond, Pathologisch Anatomisch Laboratorium Dordrecht, Zuiderziekenhuis, Sint Clara Ziekenhuis, Medisch Centrum Haaglanden, St. Streeklaboratorium Zeeland, Sint Elisabeth Ziekenhuis, Catharinaziekenhuis, Sint Maartensgasthuis and Spaarne Ziekenhuis. This work was supported by The Netherlands Organisation for Scientific Research (980–10–26) for Margreet Lüchtenborg and The Dutch Cancer Society (UM 99–1980) for Mirian Brink.

References
1.
Woutersen
RA

Appel
MJ

Garderen-Hoetmer
A

Wijnands
MV


Dietary fat and carcinogenesis
Mutat Res
1999
443
1–2
111
127

10415435


2.
Potter
JD


Nutrition and colorectal cancer
Cancer Causes Control
1996
7
1
127
146
10.1007/BF00115644

8850441


3.
Willett
WC


Diet and cancer
Oncologist
2000
5
5
393
404
10.1634/theoncologist.5-5-393

11040276


4.
Lin
J

Zhang
SM

Cook
NR

Lee
IM

Buring
JE


Dietary fat and fatty acids and risk of colorectal cancer in women
Am J Epidemiol
2004
160
10
1011
1022
10.1093/aje/kwh319

15522858


5.
Sanderson
P

Johnson
IT

Mathers
JC

Powers
HJ

Downes
CS

McGlynn
AP



Emerging diet-related surrogate end points for colorectal cancer: UK Food Standards Agency diet and colonic health workshop report
Br J Nutr
2004
91
2
315
323
10.1079/BJN20031035

14756919


6.
Vogelstein
B

Fearon
ER

Hamilton
SR

Kern
SE

Preisinger
AC

Leppert
M



Genetic alterations during colorectal-tumor development
N Engl J Med
1988
319
9
525
532

2841597


7.
Gryfe
R

Swallow
C

Bapat
B

Redston
M

Gallinger
S

Couture
J


Molecular biology of colorectal cancer
Curr Probl Cancer
1997
21
5
233
300
10.1016/S0147-0272(97)80003-7

9438104


8.
Fodde
R

Smits
R

Clevers
H


APC, signal transduction and genetic instability in colorectal cancer
Nat Rev Cancer
2001
1
1
55
67
10.1038/35094067

11900252


9.
Kuismanen
SA

Holmberg
MT

Salovaara
R

la Chapelle
A

Peltomaki
P


Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers
Am J Pathol
2000
156
5
1773
1779

10793088


10.
Breivik
J

Gaudernack
G


Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer
Adv Cancer Res
1999
76
187
212

10218102


11.
Lengauer
C

Kinzler
KW

Vogelstein
B


Genetic instability in colorectal cancers
Nature
1997
386
6625
623
627
10.1038/386623a0

9121588


12.
Shih
IM

Zhou
W

Goodman
SN

Lengauer
C

Kinzler
KW

Vogelstein
B


Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis
Cancer Res
2001
61
3
818
822

11221861


13.
Smith
G

Carey
FA

Beattie
J

Wilkie
MJ

Lightfoot
TJ

Coxhead
J



Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer
Proc Natl Acad Sci U S A
2002
99
14
9433
9438
10.1073/pnas.122612899

12093899


14.
Luchtenborg
M

Weijenberg
MP

Wark
PA

Saritas
AM

Roemen
GM

Muijen
GN



Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study
BMC Cancer
2005
5
160
10.1186/1471-2407-5-160

16356174


15.
Fearon
ER

Vogelstein
B


A genetic model for colorectal tumorigenesis
Cell
1990
61
5
759
767
10.1016/0092-8674(90)90186-I

2188735


16.
Breivik
J

Gaudernack
G


Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis
Semin Cancer Biol
1999
9
4
245
254
10.1006/scbi.1999.0123

10448112


17.
Bardelli
A

Cahill
DP

Lederer
G

Speicher
MR

Kinzler
KW

Vogelstein
B



Carcinogen-specific induction of genetic instability
Proc Natl Acad Sci USA
2001
98
10
5770
5775
10.1073/pnas.081082898

11296254


18.
Marnett
LJ


Oxy radicals, lipid peroxidation and DNA damage
Toxicology
2002
181–182
219
222
10.1016/S0300-483X(02)00448-1

12505314


19.
Niedernhofer
LJ

Daniels
JS

Rouzer
CA

Greene
RE

Marnett
LJ


Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells
J Biol Chem
2003
278
33
31426
31433
10.1074/jbc.M212549200

12775726


20.
Leuratti
C

Watson
MA

Deag
EJ

Welch
A

Singh
R

Gottschalg
E



Detection of malondialdehyde DNA adducts in human colorectal mucosa: relationship with diet and the presence of adenomas
Cancer Epidemiol Biomarkers Prev
2002
11
3
267
273

11895876


21.
Hendrickse
CW

Kelly
RW

Radley
S

Donovan
IA

Keighley
MR

Neoptolemos
JP


Lipid peroxidation and prostaglandins in colorectal cancer
Br J Surg
1994
81
8
1219
1223
10.1002/bjs.1800810849

7953368


22.
Brink
M

Weijenberg
MP

Goeij
AF

Schouten
LJ

Koedijk
FD

Roemen
GM



Fat and K-ras mutations in sporadic colorectal cancer in The Netherlands Cohort Study
Carcinogenesis
2004
25
9
1619
1628
10.1093/carcin/bgh177

15117813


23.
Brandt
PA

Goldbohm
RA

van’t Veer
P

Volovics
A

Hermus
RJ

Sturmans
F


A large-scale prospective cohort study on diet and cancer in The Netherlands
J Clin Epidemiol
1990
43
3
285
295
10.1016/0895-4356(90)90009-E

2313318


24.
Brandt
PA

Schouten
LJ

Goldbohm
RA

Dorant
E

Hunen
PM


Development of a record linkage protocol for use in the Dutch cancer registry for epidemiological research
Int J Epidemiol
1990
19
3
553
558
10.1093/ije/19.3.553

2262247


25.
Luchtenborg
M

Weijenberg
MP

Roemen
GM

Bruine
AP

Brandt
PA

Lentjes
MH



APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study
Carcinogenesis
2004
25
7
1219
1226
10.1093/carcin/bgh117

14976131


26.
Rowan
AJ

Lamlum
H

Ilyas
M

Wheeler
J

Straub
J

Papadopoulou
A



APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”
Proc Natl Acad Sci USA
2000
97
7
3352
3357
10.1073/pnas.97.7.3352

10737795


27.
Brink
M

Goeij
AF

Weijenberg
MP

Roemen
GM

Lentjes
MH

Pachen
MM



K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study
Carcinogenesis
2003
24
4
703
710
10.1093/carcin/bgg009

12727799


28.
Nevo table (1987) Dutch food composition table 1986–1986

29.
Goldbohm
RA

Brandt
PA

Brants
HA

van’t Veer
P

Al
M

Sturmans
F



Validation of a dietary questionnaire used in a large-scale prospective cohort study on diet and cancer
Eur J Clin Nutr
1994
48
4
253
265

8039485


30.
Poppel
G


Intake of trans fatty acids in western Europe: the TRANSFAIR study
Lancet
1998
351
9109
1099

9660581


31.
Willett
W


Nutritional epidemiology
1998
New York
Oxford University Press

Willett W (1998) Nutritional epidemiology. Oxford University Press, New York  

32.
Lin
DY

Wei
LJ


The robust inference for the Cox proportional hazards model
JASA
1989
84
408
1074
1078

Lin DY, Wei LJ (1989) The robust inference for the Cox proportional hazards model. JASA 84(408):1074–1078 

33.
Wei
EK

Giovannucci
E

Wu
K

Rosner
B

Fuchs
CS

Willett
WC



Comparison of risk factors for colon and rectal cancer
Int J Cancer
2004
108
3
433
442
10.1002/ijc.11540

14648711


34.
Schoenfeld
D


Partial residuals for the proportional hazards regression models
Biometrika
1982
69
1
239
241
10.1093/biomet/69.1.239

Schoenfeld D (1982) Partial residuals for the proportional hazards regression models. Biometrika 69(1):239–241 

35.
Bautista
D

Obrador
A

Moreno
V

Cabeza
E

Canet
R

Benito
E



Ki-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer
Cancer Epidemiol Biomarkers Prev
1997
6
1
57
61

8993798


36.
Diergaarde
B

Braam
H

Muijen
GN

Ligtenberg
MJ

Kok
FJ

Kampman
E


Dietary factors and microsatellite instability in sporadic colon carcinomas
Cancer Epidemiol Biomarkers Prev
2003
12
11 Pt 1
1130
1136

14652271


37.
Diergaarde
B

Tiemersma
EW

Braam
H

Van Muijen
GN

Nagengast
FM

Kok
FJ



Dietary factors and truncating APC mutations in sporadic colorectal adenomas
Int J Cancer
2005
113
1
126
132
10.1002/ijc.20533

15386431


38.
Diergaarde
B

Geloof
WL

Muijen
GN

Kok
FJ

Kampman
E


Dietary factors and the occurrence of truncating APC mutations in sporadic colon carcinomas: a Dutch population-based study
Carcinogenesis
2003
24
2
283
290
10.1093/carcin/24.2.283

12584179


39.
Kampman
E

Voskuil
DW

Kraats
AA

Balder
HF

Muijen
GN

Goldbohm
RA



Animal products and K-ras codon 12 and 13 mutations in colon carcinomas
Carcinogenesis
2000
21
2
307
309
10.1093/carcin/21.2.307

10657973


40.
Martinez
ME

Maltzman
T

Marshall
JR

Einspahr
J

Reid
ME

Sampliner
R



Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas
Cancer Res
1999
59
20
5181
5185

10537295


41.
Slattery
ML

Curtin
K

Anderson
K

Ma
KN

Edwards
S

Leppert
M



Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study
Cancer Res
2000
60
24
6935
6941

11156393


42.
Wark
PA

Kuil
W

Ploemacher
J

Muijen
GN

Mulder
CJ

Weijenberg
MP



Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas
Int J Cancer
2006
119
2
398
405
10.1002/ijc.21839

16477638


43.
Slattery
ML

Anderson
K

Curtin
K

Ma
KN

Schaffer
D

Samowitz
W


Dietary intake and microsatellite instability in colon tumors
Int J Cancer
2001
93
4
601
607
10.1002/ijc.1370

11477566


44.
Sjoblom
T

Jones
S

Wood
LD

Parsons
DW

Lin
J

Barber
TD



The consensus coding sequences of human breast and colorectal cancers
Science
2006
314
5797
268
274
10.1126/science.1133427

16959974





